loss per share compar estim ep
primarili result higher expect oper expens exceed
estim expens million higher estim
million addit collabor revenu lower expect due
chang collabor revenu recognit detail promis pipelin
regulatori updat provid includ report
adjust revenu account chang revenu
recognit outlook revenu unchang
modestli adjust estim oper expens increas
incom reflect higher estim cash balanc increas
share outstand fulli includ impact equiti offer
net effect increas loss per share increas ep
decreas loss per share decreas ep
octob cytomx file investig new drug ind applic
expect commenc dose-escal studi follow fda accept
cytomx announc expect initi clinic data part cohort
trial part monotherapi expans cohort
dose eight undisclos tumor type continu enrol
cytomx announc anticip present comprehens data updat
part part dose-escal cohort
substanti complet
develop
probodi
platform treatment cancer
platform allow drug select
activ tumor microenviron
remain inert healthi tissu
analyst certif import disclosur see disclosur
pre-clin data continu show probodi abil increas
therapeut index antibodi
immuno-oncolog antibodi therapeut continu show seriou
on-target side effect especi combin
cytomx develop probodi proprietari masked-antibodi
technolog treatment cancer compani
cytomx stage develop phase primarili
focu potenti futur revenu valu base
expect cytomx launch first product next
seven year result revenu billion
estim revenu assum success launch
howev case development-stag compani
estim carri high degre risk
initi data phase studi
launch phase studi
ind
partnership agreement other cytomx abl begin
combin studi sooner expect
cytomx clinic program advanc quickli
estim
probodi clinic develop delay
probodi shown increas therapeut index
antibodi futur pre-clin studi
phase i/ii studi fail
continu rate cytomx high-qual development-stag platform technolog
compani strong manag team eleg scienc perform anticip
compani launch first drug treatment lymphoma solid tumor
compani cytomx stage develop phase primarili focu
potenti futur revenu valu base expect cytomx launch
first product next seven year estim total revenu grow compound-annual-growth-rate
next eight year increas billion estim
revenu assum success launch howev case development-stag
compani estim nonetheless carri high degre risk
summari believ cytomx stock current trade rang reflect level
risk compani complet phase trial success therefor rate
stock perform
analysi
loss per share compar estim ep primarili
result higher expect oper expens exceed estim
 expens million higher estim million
addit collabor revenu lower expect due chang collabor
detail analysi provid exhibit
exhibit analysi compar prior period opco estim
cytomx inc nasdaq- incom statement thousand except per share data estimatedactualactu vs opco bp actuali chang bp actualq chang product relat relat good oper incom incom incom avail common share share per per share dilut compani data oppenheim co estimatesaddit inform avail upon request perform na
cytomx provid updat guidanc previous expect suffici cash
fund oper
adjust revenu account chang revenu recognit
outlook revenu unchang modestli adjust
estim oper expens increas interest incom
reflect higher estim cash balanc increas share outstand fulli includ
impact equiti offer net effect increas loss per
share increas ep decreas loss per share
decreas ep detail analysi chang outlook provid
exhibit
exhibit analysi chang estim sinc last report
cytomx inc nasdaq- incom statement thousand except per share data priorrevisedchang bp priorrevisedchang bp priorrevisedchang product relat relat good oper incom incom incom avail common share share per per share dilut compani data oppenheim co estimatesaddit inform avail upon request perform na
exhibit analysi chang estim sinc last report
cytomx inc nasdaq-ctmx leah rush cannincom statement oppenheim co thousand except per share bp priorrevisedchang bp priorrevisedchang bp priorrevisedchang bp priorrevisedchang product relat relat good oper incom incom incom avail common share share per per share dilut compani data oppenheim co estimatesaddit inform avail upon request cytomx
cytomx announc websit
today cytomx announc part monotherapi dose-escal cohort
phase i/ii trial
tumor initi dose mg/kg anticip top dose
mg/kg enrol dose level mg/kg novemb
cytomx also announc part cohort patient
express tumor trial initi mg/kg
enrol dose level mg /kg novemb
cytomx announc seven tumor type investig
trial breast cancer ovarian cancer castration-
resist prostat cancer cholangiocarcinoma endometri cancer head
neck cancer non-smal cell lung cancer
cytomx announc disclos one current undisclos
tumor type part cohort trial
cytomx announc continu enrol dose patient combin
trial plu zelboraf vemurafenib patient braf-posit
juli cytomx initi part phase i/ii trial cx-
pdc collabor
cytomx announc expect five activ clinic program year-
end studi
cytomxclin trialsproduct studyindicationpartner/otherdiscoverylead tumor engag solid tumor w/ nivolumabbristol-my squibbimmunotherapi targetsbristol-my squibbpdcspdcsimmunogenprocar-nkmd probodi bi-specificamgenpre-clin perform na
fda decis file data releas updat
octob cytomx file investig new drug ind applic cx-
expect commenc dose-escal studi follow fda
announc websit
announc websit
today cytomx announc clinic translat data on-going
phase i/ii trial evalu present
poster rapid-fir oral present societi immunotherapi
cancer annual meet novemb washington dc
cytomx host analyst event novemeb meet
cytomx announc expect ininit clinic data part cohort
trial part monotherapi expans cohort
dose eight undisclos tumor type continu enrol
product candidateindicationdecisionexpect approvalawait acceptanceproduct candidateindicationfilingexpect candidatestudyindicationexpect time solid tumorsfollow-up data esmo programsitc dpreliminari data apreliminari data part data cytomx
cytomx announc anticip present comprehens data updat
part part dose-escal cohort
substanti complet
octob esmo cytomx present clinic result two arm
on-going phase i/ii studi evalu monotherapi
combin yervoy ipilimumab zelboraf vemurafenib
patient advanc unresect solid tumor data base
august cut-off date inform see note updat data
proclaim studi present esmo support monotherapi
checkpoint combin develop
provid summari financi outlook full financi
model product detail avail upon request
cytomx inc nasdaq-ctmx leah rush cannestim sale earningsoppenheim co million except per share statement product relat growth incom incom share share per per share dilut sheet stockhold statementoper cash flow per cash flow per compani data oppenheim co estimatesaddit inform avail upon request cytomx
stock price compani mention report
